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Abstract
Epithelial-mesenchymal transition (EMT) is a crucial pathological event in cancer, particu-
larly in tumor cell budding and metastasis. Therefore, control of EMT can represent a novel
therapeutic strategy in cancer. Here, we introduce an innovative three-dimensional (3D)
high-throughput screening (HTS) system that leads to an identification of EMT inhibitors.
For the establishment of the novel 3D-HTS system, we chose NanoCulture Plates (NCP)
that provided a gel-freemicro-patterned scaffold for cells and were independent of other
spheroid formation systems using soft-agar. In the NCP-based 3D cell culture system,
A549 lung cancer cells migrated, gathered, and then formedmultiple spheroids within 7
days. Live cell imaging experiments showed that an established EMT-inducer TGF-β pro-
moted peripheral cells around the core of spheroids to acquire mesenchymal spindle
shapes, loss of intercellular adhesion, and migration from the spheroids. Along with such
morphological change, EMT-related gene expression signatures were altered, particularly
alteration of mRNA levels of ECAD/CDH1, NCAD/CDH2, VIM and ZEB1/TCF8. These
EMT-related phenotypic changes were blocked by SB431542, a TGF-βreceptor I
(TGFβR1) inhibitor. Inside of the spheroids were highly hypoxic; in contrast, spheroid-
derived peripheralmigrating cells were normoxic, revealed by visualization and quantifica-
tion using Hypoxia Probe. Thus, TGF-β-triggeredEMT caused spheroid hypoplasia and
loss of hypoxia. Spheroid EMT inhibitory (SEMTIN) activity of SB431542 was calculated
from fluorescence intensities of the Hypoxia Probe, and then was utilized in a drug screen-
ing of EMT-inhibitory small molecule compounds. In a pilot screening, 9 of 1,330
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compounds were above the thresholds of the SEMTIN activity and cell viability. Finally, two
compounds SB-525334 and SU9516 showed SEMTIN activities in a dose dependentman-
ner. SB-525334was a known TGFβR1 inhibitor. SU9516 was a cyclin-dependent kinase 2
(CDK2) inhibitor, which we showed also had an EMT-inhibitory activity. The half maximal
inhibitory concentration (IC50) of SB-525334 and SU9516 were 0.31 μMand 1.21 μM,
respectively, while IC50 of SB431542 was 2.38 μM. Taken together, it was shown that this
3D NCP-based HTS systemwas useful for screening of EMT-regulatory drugs.
Introduction
Cell-basedassays for a development of anti-cancer drugs have beenmostly performed in
monolayer culture condition [1]. On the one hand, widely attached cells have been easily han-
dled on such two-dimensional (2D) cell culture plates/dishes, and thus, the 2D cell culture
methods have been suitable for analysis of particularmolecules in detail. On the other hand,
the 2D cell culture have been known to enhance integrin signaling, thus to mask some of the
biological activities of tumor cells [2]. Therefore, it has been implicated that physical contact of
cells with tissue culture plates might result in artificial alteration of tumor cells. In contrast,
other researchers have reported that three-dimensional (3D) cell cultures can replicate the
intratumor microenvironment [3–5]. These findings suggest the importance of 3D cell culture
conditions for evaluation of the cellular phenotype and of chemical compounds and/or cyto-
kines. Recently, Kumar et. al. reported that mesenchymal transition of non-small cell lung car-
cinoma (NSCLC) cell lines were much more efficiently induced on 3D cell culture condition
than 2D [6]. These reported persuaded us to develop a novel 3D screening system.
NanoCulture Plate (NCP) is a cell/tissue culture plate with patterned nano-scale grids on
the plate base [7]. This mogul field on the NCPs restricts cells from sprawling on the base and
enables tumor cells to migrate more than the monolayer layer cell culture system [8]. Cells
migrate from a scaffold to another scaffold on the grid in the NCPs more actively than cells cul-
tured on 2D plate. The increasedmigration and lesser attachment of tumor cells on the NCPs
concurrently enable tumor cells to form 3D spheroids in FBS-containingmedium. Another
advantage of the NCPs in tumor and cell biology is that NCPs is useful without gel materials
[7]. Cells cultured on NCPs have high proliferation activity as same as on 2D cell culture condi-
tions. The NCP-based cell-culture system can also be useful for selection of malignant cells that
can grow in anchoring-independent condition as shown in soft-agar. The NCP-based 3D cell-
culture method is suitable for assessing morphological change, which is a key phenomenon in
tumor progression. Epithelial-mesenchymal transition (EMT) is a morphological change of tis-
sues/cells from an epithelial form to a fibroblast-likemesenchymal form. This biological event
has been shown to participate in physiological development, tissue regeneration and tumor
progression, particularly in tumor budding and metastasis [9–11]. In addition to the morpho-
logical changes, key biomarkers in the steps of EMT have been established including cell adhe-
sion molecules and, transcription factors and kinases [12]. Tumor cells along with progression
of EMT assume a spindled shape, lose desmosomes and adherence junctions, and express mes-
enchymal molecules such as microtubule vimentin and a zinc-finger E-box transcription factor
ZEB-1/TCF8 [9,13]. The expression of EMT biomarkers has been reported to be correlated
with drug resistance [14–18]. Vice versa, inhibition of EMTmay interfere with tumor progres-
sion and drug resistance. Transforming Growth Factor-β (TGF-β) signaling have been shown
to be involved in a large number of cellular processes including EMT [19]. TGF-β signaling
inhibitors have been evaluated in oncologic pre-clinical and clinical studies [20,21].
3D ScreeningSystem for EMT Inhibitors
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In this paper, we firstly developed an in vitro EMTmodel on NCP-based 3D cell culture sys-
tem and then established a novel 3D high-throughput screening (HTS) system for screening of
EMT inhibitors. In order to quantitate sizes and intercellular adhesion of 3D spheroid, we also
utilizedHypoxia Probes, an agent that is composed of a phosphorescent light–emitting iridium
complexes, whose emitting energy is quenched by oxygen molecules in normoxic condition
[22]. Using such materials and system, we screened novel EMT-inhibitory compounds from a
library of 1,330 pharmacologically active compounds and then obtained screening hits that
indeed inhibited EMT.
Materials andMethods
Reagents and antibodies
Human recombinant TGF-β2 (R&D systems, Minneapolis, MN) stock solution (20 μg/mL)
was prepared with 0.1% BSA/4 mMHCL according to manufacturer’s procedure, and used at a
final concentration of 5 ng/mL An ALK inhibitor, SB431542 was obtained from Stemgent
(Cambridge,MA). SB-525334 was from Sigma-Aldrich (St. Louis, MO). SU9516 was from
Merck Millipore (Billerica,MA). These compound were dissolved in DMSO at 10 mM as a
stock solution and diluted when used. Antibodies used were: E-cadherin (mouse monoclonal,
clone 36/E-Cadherin), obtained from BD Biosciences (San Jose, CA). An anti-β-actin antibody
(mouse monoclonal, clone AC-15) was obtained from Sigma–Aldrich (St. Louis,MO). All sec-
ondary horseradish peroxidase-conjugated antibodies were obtained from Jackson ImmunoRe-
search (West Grove, PA). Alexa 488-conjugated secondary antibody was obtained from Abcam
(Cambridge,MA).
Cell culture, control of EMT status
We used A549 human lung carcinoma cell line and 4 human pancreatic cancer cell lines:
Capan-2 well-differentiated adenocarcinoma derived from a primary tumor, AsPC-1, PANC-
1, and MIA PaCa-2 poorly differentiated adenocarcinoma derived from primary tumor. These
cell lines were obtained from American Type Culture Collection and maintained on plastic tis-
sue culture plates in Dulbecco'smodifiedEagle's medium (DMEM, Nisshin EM, Tokyo, Japan)
supplemented with 10% inactivated fetal bovine serum. Induction of EMT was performed in
DMEM containing 5% fetal bovine serumwith 5 ng/mL TGF-β2 (R&D Systems, MN).
SB431542 was used as positive control at 10 μM. Negative control is the vehicle, DMSO. Nano-
Culture Plate (SCIVAX Life Sciences, Kanagawa, Japan) was used as 3D cell culture system.
Cells were seeded in 96-well plate at a density of 10,000 cells/well or in 384 well plate at a den-
sity of 3,000 cells/well, respectively.
Live-Cell Imaging
After 3 days culturing, spheroids were treated with or without TGF-β2. Then time-lapse images
of these spheroids were filmed using a BioStation CT (Nikon Co., Tokyo, Japan) every 2 hours
for 4 days.
RNA extraction and quantitative RT-PCR
Total RNA was isolated with the RNeasy Plus Mini Kit, according to the manufacturer’s
instructions (Qiagen, Hilden, Germany). Reverse transcription was performedwith Prime-
Script™ RT reagent Kit (TaKaRa, Shiga, Japan) including a mixture of oligo dT and random
primers. Real-time PCR was carried out with the synthesized cDNA, SYBR1 Premix Ex Taq™
II (Tli RNaseH Plus) and primer sets in a Thermal Cycler Dice Real Time System (TaKaRa,
3D ScreeningSystem for EMT Inhibitors
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Shiga, Japan). Expression data were normalized to the geometricmean of housekeeping gene
TBP to control the variability in expression levels and were analyzed using the 2 -ΔΔCT
method describedby Livak and Schmittgen [23].
The following primer pairs were used:TBP forward, 5’-TGCTGCGGTAATCATGAGG
ATA, TBP reverse, 5’-TGAAGTCCAAGAACTTAGCTGGAA (TaKaRa Shiga, Japan), CHD1
forward, 5'-ATTGCAAATTCCTGCCATTC, CDH1 reverse TCCTCCGAAGAAACAGC
AAG, CDH2 forward 5'-AGGTTTGCCAGTGTGACTCC,CDH2 reverse 5'-CCACAAACAT
CAGCACAAGG, VIM forward 5'-AGACAGGTGCAGTCCCTCAC, VIM reverse 5'-GCTTC
AACGGCAAAGTTCTC,ZEB1/TCF8 forward 5'-GGAAAGCGCTTCTCACACTC, and
ZEB1/TCF8 reverse 5'-GTCACGTTCTTCCGCTTCTC.
Immunoblotting
Cells were lysed within Cell Lysis Buffer (10×) (Cell Signaling Technologies) according to man-
ufacturer’s protocol. And 5 μg protein samples were separated by SDS–PAGE 10% and trans-
ferred to a 0.45 μm pore size PVDFmembrane (EMDMillipore, MA). Blocking and antibody
reaction steps were carried out in skimmilk solution. After antibody incubation, peroxidase
activity was detected via chemiluminescence (ECL reagent; Bio-Rad, Hercules, CA).
Hypoxia imaging and quantification
Hypoxia Probe (SCIVAX USA,Woburn, MA) were dissolved in DMSO at 1 mM as a stock
solution and stored at -20°C in the dark. The stock solution was diluted with culture medium
and added to the culturingmedium at a final concentration of 2 μM per well. One day after
the addition, spheroid images and the fluorescent intensities of Hypoxia Probe were obtained
with a cell imaging equipment, Celigo (Nexelom, Lawrence, MA). Integrated fluorescent inten-
sities (IFI) from the probes in a whole well were calculated by multiplying the number of seg-
mented spheroids by an average of mean intensity becausemultiple spheroids were included in
one well.
Pilot screening targeted to 1,330 pharmacologicallyactive compounds
We chose 10 μM SB431542 as a positive control. Dimethyl sulfoxide (DMSO), a vehicle of
compounds, was used as a negative control. Each compound was diluted with DMSO at
400 μM in Polypropylene 384 well V-bottom plates as daughter plates. Positive/negative con-
trols were added in the each daughter plates. Pre-cultured cells were harvested by 0.05% Tryp-
sin/0.5 mM EDTA solution and seeded into NCP 384 well plate at a concentration of 3,000
cells/well/45 μL medium. Three days later, drugs of daughter plates with or without TGF-β2
were diluted with culture medium. Then the solution was added into the wells in 5 μL each
(final concentration of chemical compounds, DMSO and TGF-β2 were 1 μM, 0.25% and 5 ng/
mL, respectively). After the treatment for 3 days, spheroids/cells were treated with 2 μM Hyp-
oxia Probe for overnight. The signal intensity was measured with Celigo. Then finally, cell via-
bility was evaluated by luminescenceATP assay, as describedherein below.
Calculation of Spheroid EMT inhibitoryactivity
Spheroid EMT inhibitory (SEMTIN) activity of each target compounds were calculated from
IFIs of target compounds and positive/negative-controls for adequate evaluation of these target
3D ScreeningSystem for EMT Inhibitors
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compounds. The formula is as follow:
SEMTIN activity ¼
IFIðw=o TGF  b2Þ   IFIðwith TGF  b2Þ  a
l
 100 %ð Þ
α is a reciprocal EMT inducible efficiencyon negative control, explained as IFI (with TGF-β2)
 IFI (w/o TGF-β2).
λ is an amount of inhibited EMT on positive control, explained as IFI (w/o TGF-β2) −
IFI (with TGF-β2) × α
Cell Survival Assay
The viability of the cells was estimated by quantification of the ATP present using a CellTiter-
Glo (CTG) Luminescent Cell Viability Assay (Promega Co., Madison,WI), a reagent with a
luminescent readout that reflects cell viability via the measurement of ATP metabolism. A half
of culture supplement (25 μL) were removed and an equal volume of CTG solution was added
to each well, and then suspended by liquid handler. The plate was rocked on a shaker for 10
min and incubated for an additional 20 min at 37°C. Luminescent measurements were done on
Infinite M200 (Tecan, Männedorf, Switzerland), plate reader. For assays measuring toxicity
effects, all values were normalized to the mock-treated conditions.
Immunofluorescence staining for E-cadherin and quantification
Cells were seeded onto NCP or 8 well chamber slide (BD Biosciences, San Diego, CA). After
treatment with TGF-β2 and with/without drugs, spheroids were directly fixed on NCPs or
8-well chamber slide by adding 1/10 volume of 40% formaldehyde solution into the culture
medium for 15 min. Cells were permeabilizedwith 0.2% Tween-20 in PBS(-) for 10 min at RT.
Then, spheroids were incubated with the primary antibody for E-cadherin diluted in PBS for
overnight at 4°C, followed by incubation with the secondary antibody for 1 hour at RT. And
the nuclei were counterstained with DAPI. Immunoreactivities were visualizedwith imaging
cytometer Celigo for 3D, or confocal-microscopy FLUOVIEW FV10i (Olympus, Tokyo,
Japan) for 2D. Fluorescence signal of E-cadherin and DAPI in a whole well were integrated. To
calculate E-cadherin expression level per cell, the integrated E-cadherin fluorescent signal was
divided by the integrated DAPI signal, and then compared with the vehicle control (0.1% BSA/
4 mMHCL and DMSO)
Results
Development of in vitro 3D EMTmodel on NanoCulturePlate
In order to develop the 3D in vitro EMTmodel, we usedNanoCulture Plate on which tumor
cells could easily migrate and form spheroids. On the NCPs, a human NSCLC cell line, A549,
rapidly migrated, aggregated and formed spheroids of varying size (Fig 1A, lower left). TGF-β
has been known to induce EMT [24,25]. We treated A549 cells with TGF-β2 on 2D and 3D
plate and evaluated whether TGF-β2 induces EMT in 3D-NCP culture condition. The cells
treated with TGF-β2 on 2D condition appeared to adopt fibroblastic spindle shapes (Fig 1A,
upper right). In contrast, cells treated with TGF-β2 did not form spheroids in the 3D-NCP con-
dition. These cells formed loose clusters with scarce intercellular adhesion. A few single cells
had spindle shapes (Fig 1A, lower right). For a greater understanding of the spheroid morpho-
logical change induced by the TGF-β2 treatment, a time-lapse observationwas then conducted.
We observed that TGF-β2 treatment prompted cells to spread out from spheroids, declined
intercellular adherence and reduced spheroid sizes, in contrast to non-treatment spheroids
3D ScreeningSystem for EMT Inhibitors
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Fig 1. Epithelial tomesenchymal transition (EMT) on NanoCulture Plate (NCP). (A) A549 cells were grown in 2D or
3D-NCP conditions with or without TGF-β2 for 4 days. The cells treatedwith TGF-β2 on 2D condition appeared to present
3D ScreeningSystem for EMT Inhibitors
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(Fig 1B and S1 and S2 Movies). Thus, the A549 cells formed 3D spheroids on the NCPs, but
the cells fail to form spheroids after TGF-β2 treatment. Treatment with TGF-β2 appeared to
inhibit interspheroid fusions and to increase cellular budding and subsequent release from the
spheroids, which made the spheroid surface rough. Such changes around the surface of the
spheroids appeared to block the formation of larger spheroids and finally to reduce sizes of the
aggregated spheroids compared to the control.
Next, we confirmed the effect of TGF-β receptor type I (TGFβR1) inhibitor SB431542 on
this change of spheroid morphology. SB431542 inhibited the spheroid morphological change
caused by TGF-β2 (Fig 1C). Furthermore, we examined epithelial and mesenchymal gene
expressions in the A549 cells treated with TGF-β2 only and TGF-β2 plus SB431542 compared
to non-treated control on the NCPs. For qRT-PCR, TBPwas chosen as an internal control
gene (S1 Fig). The mRNA level of ECAD/CDH1, the epithelial marker, was decreased by treat-
ment with TGF-β2. In contrast, mRNA levels of NCAD/CDH2,VIM and ZEB1/TCF8were
increased by the treatment of TGF-β2 (Fig 1D). These alterations in EMT-related gene expres-
sion were inhibited by the addition of SB431542 (Fig 1C and 1D). These results showed that
the spheroid morphological change, which was induced with TGF-β2, was caused as the result
of EMT at a molecular level. And as a result, we have effectively established an in vitro EMT
model on NCP.
Correlationbetween hypoxia and EMTmodel on NCP
It has been shown that tumor progression is a process where well-differentiated normal epithe-
lial or ductal cells de-differentiates into mesenchymal-like cells. Many de-differentiation
changes in tumor cells have been explained by the loss of the epithelial markers, such as E-cad-
herin, and by the gain of mesenchymal markers, such as N-cadherin [26,27]. E-cadherin, the
inter-cellular adhesion molecule is essential not only for maintenance of epithelial status but
also for spheroid formation and morphology (cell-cell connection) [28–30]. Hypoxic status in
spheroids have been reported as below. Sutherland et al. reported that the center of spheroids
can have a more hypoxic status compared with the peripheral layers of the spheroid [31]. War-
tenberg et al. reported the correlation between spheroid size and hypoxia condition [32]. Park
et al. described that round and compact spheroids exhibited highly hypoxic inner core [33]. In
relation to these evidences, we examined E-cadherin expression levels, spheroid morphology,
and hypoxic status of several pancreatic cancer cell lines with different differentiation levels on
the 3D-NCP system [25,26]. To investigate correlativity between differentiation levels and
spheroid features, we first observed cellular shapes of Capan-2, AsPC-1, PANC-1 and MIA
PaCa-2 pancreatic cancer cell lines on 2D culture condition. Among these 4 cell lines, Capan-2
showed the most epithelial shapes, AsPC-1 and PANC-1 showed an intermediate epithelial
morphology, and MIA PaCa-2 showed the most mesenchymal spindle shape in 2D culture
condition (Fig 2A). Next, we compared E-cadherin expression levels of these cell lines. The
expression level of E-cadherinwas the highest in Capan-2 and the lowest in MIA PaCa-2
(Capan-2>AsPC-1, PANC-1>MIA PaCa-2) (Fig 2B), indicated that Capan-2 was epithelial,
fibroblastic spindle shape. In the 3D-NCP condition, TGF-β2-treated spheroid cells appeared to spread out from spheroids,
and spheroid sizes were reduced. (B) Representative images of kinetic morphology change. Cells were pre-cultivated on
NCP for 3 days and then treatedwith TGF-β2 for 4 days. Arrowheads indicate spheroids that fused into one spheroid.
Arrow indicate spheroid collapse induced by the addition of TGF-β2. Scale bars, 200 μm. Live-cell imaging video is
available in S1 and S2Movies. (C) A549 cells were culturedwith or without TGF-β2 only or TGF-β2 + SB431542 for 4 days.
Representative imageswere shown. Scale bar, 200 μm. (D)mRNA levels of ECAD/CDH1,NCAD/CDH2, VIM and ZEB1/
TCF8were quantifiedwith real-timeqRT-PCR analyses. Values were normalized to TBP levels, and then were shown as
themean of fold change to vehicle control ± SD of three independent experiments
doi:10.1371/journal.pone.0162394.g001
3D ScreeningSystem for EMT Inhibitors
PLOSONE | DOI:10.1371/journal.pone.0162394 September 13, 2016 7 / 18
MIA PaCa-2 was mesenchymal, and AsPC-1 and PANC-1 were intermediates.We next cul-
tured three cell lines on NCPs and examined the spheroid morphology and hypoxic levels of
these cell lines, using Hypoxia Probe After cultured for 7 days on NCPs, these cell lines formed
Fig 2. Hypoxia level of spheroidswas positively correlatedwith E-cadherin level in pancreatic cancer cell lines. (A) Representative phase
contrast images of four types of pancreatic cancer cell lines cultured on 2D condition. Scale bar, 100 μm. (B)Western blotting analysis of E-cadherin
in the 4 types of pancreatic cancer cell lines cultured on NCPs for 7 days. β-actin was examined as the loading control. Signal intensities were
quantified, and relative values were shown on the graph. (C) Representative hypoxic images of pancreatic cancer cell lines cultured on NCPs.
Hypoxia Probewas added to the culturemediumand visualized under fluorescence microscopy, shown in red. The fluorescence and bright field
imageswere merged. Scale bar, 200 μm. (D) Hypoxia levels among the cell lines. Integrated fluorescent intensities (IFI) of the Hypoxia Probe taken
in spheroidswere calculated as described in Materials andMethods. N = 3. Data are mean ± SD.
doi:10.1371/journal.pone.0162394.g002
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spheroids/cell-aggregates (Fig 2C and S2 Fig). Capan-2 formed large and smooth surface
spheroids, PANC-1 and MIA PaCa-2 formed small size spheroids in loose cell-to-cell adher-
ence (Fig 2C). Thus, these cell lines formed different types of spheroids correlated with E-cad-
herin expression levels. Next, we evaluated integrated fluorescence intensities (IFI) of the
Hypoxia Probe taken up into spheroids. Among these cell lines, Capan-2 spheroids showed the
highest degree of hypoxia, PANC-1 spheroids were of intermediate degree, and MIA PaCa-2
spheroids were the most normoxic (Fig 2D). These results indicated that Capan-2 had the
highest cell density per spheroid among these 3 cell lines. Taken together, these experiments
indicated that the hypoxia levels of spheroids tend to be positively correlated with E-cadherin
expression levels and with the morphology of spheroids with higher intercellular adhesion lev-
els and spheroid volume.
Next, in order to clarify the relation between the degrees of hypoxia and EMT, we quanti-
tated hypoxia levels of the A549 spheroids treated with various concentrations of TGF-β2.
Hypoxia levels within the cells/spheroids were decreased in a dose-dependentmanner of TGF-
β2 treatment (Fig 3A). Inversely, the hypoxia levels reduced with TGF-β2 were increased by
the treatment with SB431542 in a dose-dependentmanner (Fig 3B and 3C). Besides, the cellu-
lar viabilities were not significantly altered by the increasing concentrations of either TGF-β2
Fig 3. Hypoxia level of A549 spheroidwas declinedwith TGF-β2and elevated with SB431542. (A) A549 spheroids cultured on NCP for 3 days
were stimulatedwith TGF-β2 for 4 days in indicated concentrations. Hypoxia Probewas then added. Integrated fluorescent intensities (IFI) of Hypoxia
Probewere reduced in a dose dependingmannerwithout affecting viability. (B) A549 spheroidswere treatedwith TGF-β2 (5 ng/mL) and indicated
concentration of SB431542 for 4 days. IFI of Hypoxia Probewere increased in a dose depending mannerwithout affecting viability. N = 3. Data are
mean ± SD. (C) Representative images of hypoxic spheroids restituted by SB431542. A549 spheroidswere treatedwith 5 ng/mL TGF-β2 and
SB431542 at indicated concentrations. Hypoxia levels were visualized with Hypoxia Probe in red color Scale bars, 200 μm.
doi:10.1371/journal.pone.0162394.g003
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or SB431542 (Fig 3). Thus, the quantification of the hypoxia level using Hypoxia Probe may be
useful as an indicator of spheroid formation along with the increase in intercellular adhesion.
This assessment using the Hypoxic Probe could be helpful for assessment of EMT inhibitors by
HTS.
Screening of potential EMT inhibitors, and validation of hits
Finally, we developed a unique assay system for screening EMT inhibitors using the in vitro
EMTmodel and monitoring hypoxia condition of inside spheroid (Fig 4A). For a proof-of-
concept of this assay system, we conducted a pilot screening using a chemical library of 1,330
pharmacologically active compounds consist of LOPAC 1280 and Prestwick Chemical Library,
and the strategy of this screening was shown in Fig 4B. IFI can be affected by auto-fluorescence
of the compounds and of cells including dead cells induced by compounds. These factors can
encompass false negative and false positive, respectively. In order to evaluate the effect of com-
pounds on the spheroid hypoplasia precisely, spheroid EMT inhibitory (SEMTIN) activity of
each target compound was calculated from IFI as described in Materials and Methods. As a
result of the screening, 9 compounds were selected as hit compounds (the thresholds of SEM-
TIN activity and viability are 15.9% (mean + 3SD) and 71.4% (mean − 3SD), respectively (Fig
4B and Fig 5). SB-525334 which is a potent ALK5/type I TGF-β-receptor kinase inhibitor [34],
was included in the hit compounds. This result validated this system worked as a screening
assay for EMT inhibitors.
We then chose 4 compounds, SB-525334, SU9516, GR 127935 hydrochloride and Ebastine,
for further validation. In the validation of the screening, we evaluated the dose-dependent
manner of these compounds both on SEMTIN activity and cell viability (Fig 6). (Effects of
Fig 4. Procedures for screeningand validationof EMT inhibitors. (A) A Scheme of EMT inhibitor screening using NCP and Hypoxia Probe.
TGF-β2 (5 ng/mL) and drugs (1 μM)were added at day 3 after seeding of A549 cells. SB431542was used as a positive control. Hypoxia Probewas
added at day 6, and then cell viability were evaluated at day 7. (B) A schematic overview of EMT inhibitor screening of 1,330 compounds. We provided
thresholds as more than 15.9%Cell viability andmore than 71.4%SEMTIN activity. Nine compounds were over the thresholds. Of these, 4
compoundswere selected for validation. Of these, 2 compounds showed the SEMTIN activity.
doi:10.1371/journal.pone.0162394.g004
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these drugs to spheroids, which were not treated with TGF-β2 were showed in S3 Fig). A549
cells formed spheroids in treatment with SB-525334 and SU9516 in dose-dependentmanners
(Fig 6A). The SEMTIN activities of these compounds were also dose dependent (Fig 6B). These
data implied that these two compounds inhibited EMT. The SEMTIN activities of each com-
pound were calculated in respect of 10 μM positive control (SB431542). The SEMTIN activity
IC50 of SB-525334 and SB431542 were 0.31 μM and 2.38 μM, respectively (Fig 6B). Thus, the
identified SB-525334 showed much higher SEMTIN activity than the control SB431542. The
SEMTIN activity IC50 value of SU9516 was 1.21 μM, which was comparable to the value of
SB431542 (Fig 6B) while SU9516 inhibited EMT at lower concentration (5 μM or less) and
reduced cell viability at higher concentration (over 10 μM) compared to the control SB431542
(Fig 6C). These results indicated that SU9516 had both efficient SEMTIN activity and higher
cytotoxicity. Although we confirmed that these two compounds had higher SEMTIN activities
compared to the positive control, GR 127935 and Ebastine showed only slight SEMTIN activity
approximately 15% at 5 μM compared to positive control (Fig 6B). Therefore, we acquired at
least two potential candidates for novel EMT inhibitors in this pilot screening.
Furthermore, we examined whether SU 9516 could alter expression levels of EMTmarkers.
Immunofluorescence revealed that E-cadherin expression level in A549 spheroids was reduced
by treatment with TGF-β2, and SU 9516 could reinstate TGF-β2-triggered E-cadherin dimin-
ishment at a part and inhibited spheroid hypoplasia (Fig 7A and 7B). Next, we examined E-
cadherin expression and localizationwith confocal microscopy in order to evaluate the EMT
inhibitory activity of SU 9516 in 2D cell culture condition. E-cadherin expression level in A549
Fig 5. Pilot screeningof EMT inhibitors from 1,330 pharmacologically active compounds.Scatter plots was
shown. The x-axis indicates the EMT inhibitory efficiency, which was calculated as described in Materials and
Methods. These data were the mean value of the independent two experiments. SB-525334 (a potent ALK5/type I
TGF-β-receptor kinase inhibitor),SU9516 (a cyclin-dependent kinase 2 (CDK2) inhibitor), GR 127935 (A selective
and potent 5-HT1B/1D serotonin receptor antagonist) and Ebastine (a histamineH1-receptorantagonist) as
indicatedwere selected for validation.
doi:10.1371/journal.pone.0162394.g005
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Fig 6. Dose dependencyof SEMTIN activity of screened compounds. (A) Representative images of spheroids that was altered by drugs.
Spheroids were treatedwith 5 ng/mL TGF-β2 and each drug at indicated concentrations. Hypoxia levels of spheroidswere measured and shown in
red. Scale bars, 200 μm. (B) Dose-dependent SEMTIN activities of the compounds. SB431542 is a positive control. SEMTIN activity IC50 of SB-
525334, SU9516, and SB431542 were 0.31 μM, 1.21 μM, and 2.38 μM, respectively. N = 4. Data aremean ± SD. (C) Cellular viability under the
exposure of compounds.
doi:10.1371/journal.pone.0162394.g006
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Fig 7. Validation of EMT inhibitoryactivities of screened compound, SU 9516. (A) Representative images of
immunofluorescence for E-cadherinof 3D cultured cells. A549 spheroids treatedwith or without TGF-β2 (5 ng/mL)
3D ScreeningSystem for EMT Inhibitors
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cells was reduced by the treatment with TGFβ2. SU 9516 appeared to inhibit the TGFβ-trig-
gered disappearance of E-cadherin on the cell surface (Fig 7C). These results indicated that SU
9516, which was one of hit compounds from the pilot screening of EMT inhibitors, indeed had
EMT inhibitory activity.
Discussion
Several efforts at discovering anti-cancer drug including the EMT inhibiting concept have been
conducted [18,20]. Chua et al. reported a development of a method screening EMT inhibitor
by calculating cell motility under 2D cell culture condition [35]. It is known that 3D cell culture
models are superior at recapitulating in vivo like growth and differentiation of tissues as com-
pared to 2D models [36]. Therefore, some researchers have tried to develop 3D-based assay
systems. Aref et al. reported an another assay system using a microfluidic device in coculture
tumor cells with human umbilical vascular endothelial cells (HUVECs), in which system cell
motility in 3D hydrogel can be evaluated [37]. However, these systems needed a specialized
kind of equipment. Li Q et al. presented the other EMT inhibitor screeningmethod, which
does not need any special equipment. Their system was based on the evaluation of vimentin, a
classic mesenchymal marker, expressed in MDA-MB-231 breast carcinoma cell line in agarose/
ECM-hydrogel 3D cell culture system [38]. However, all these screeningmethods require
reporter gene transfectants. Compared to these screeningmethods, our novel screening system
in this paper does not require transfection or complicated devices.
Analyzing expression levels of E-cadherin,N-cadherin and vimentin is a reasonable
approach. However, qRT-PCR and western blotting analyses of these factors are not efficient
methods for HTS of EMT inhibitors or screening of anti-cancer drug.We needed simpler,
HTS-compatible, and 3D assay system for development of EMT inhibitors. We reported in this
paper the simplest assay developed so far, using commercially available plates and probe. This
unique 3D-NCP allows cells to migrate due to reduced adhesion to the well surface compared
to popular 2D plates. This character of the 3D-NCP increases cellular motility so that cells
have more chances to attach and adhere each other and form spheroids. Therefore, we were
enabled to examine spheroid morphology and hypoxia status inside. Finally, we can utilize the
Hypoxia Probe, a live-cell imaging probe for hypoxia sensing, to evaluate the levels of EMT in
the cells. The Hypoxia Probe does not require washout step. This character of the probe allows
us to perform “add-only” assays that are suitable for efficient HTS. Another advantage of the
Hypoxia Probe is low toxicity. We can, therefore, do endpoint validation assays due to this
character of the Hypoxia Probe. Thus, researchers can further use the cells for cross-validation
such as cell viability assay and gene expression determination after the HTS screening assay.
We screened a 1,330 member chemical library to evaluate the validity of this innovative 3D
HTP screening system, and at least two compounds, SB-525334 and SU9516, showed the
potential EMT inhibitory activity (Figs 6 and 7). SB-525334 is known as a TGFβR1 inhibitor,
and IC50 value of SB-525334 and SB431542 in the kinase activity were 14.3 nM [32] and 25 nM
[39], respectively. Laping et al. demonstrated that SB-525334 significantly diminished tumor
incidence,multiplicity, and reduced the size of leiomyoma tumors [40]. Another hit compound
SU9516 showed EMT inhibitory activity indeed. However, it seemed that the activity in 3D cell
and SU 9516 in indicated concentration were visualized by immunofluorescence for E-cadherin (green) and with
DAPI (blue). (B) E-cadherin expression levels in the 3D culture system. E-cadherin signal intensity in a whole well
was integrated and divided by integrated DAPI signal. The relative values were shown as E-cadherinexpression
change to the vehicle control ± SD of four wells. (C) Representative images of immunofluorescence for E-cadherin of
2D cultured cells. E-cadherin at the plasmamembrane (green) and DAPI counter-stained nucleus (blue) were
visualized by confocal microscopy. Scale bars, 50 μm.
doi:10.1371/journal.pone.0162394.g007
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culture condition was lower than 2D (Fig 7). The different activitiesmay result from differences
in intracellular signaling conditions between 3D and 2D [2,6,41]. SU 9516 was a CDK2 inhibi-
tor involved in TGF-β signaling pathway [42,43]. It was also reported that SU9516 showed
cytotoxicity to several types of cancers [44,45]. Opyrchal et al. reported that this compound
selectively targeted CD44+/CD24-/Low cancer stem cell (CSC)-like subpopulation and restored
chemoresistance in inflammatory breast cancer [46]. The relation betweenCSC and EMT has
not been clarified yet and is under investigation. However, CSC and EMT cell phenotypes over-
lap [18,47]. These considerations suggested SU9516 to be an intense candidate for anti-cancer/
anti-metastasis therapeutic agents.
In conclusion, we have introduced a straightforward 3D culture-basedHTS-compatible
EMT assay. This assay system worked for in vitro and rapid screening of EMT inhibitors that
target the TGF-β signaling pathway. Users might set up a dynamic range suitable for their own
assay system when applying this method to other cell types or cytokines. This systemmay pro-
mote the development of drugs for tumor metastasis through discovering novel molecular tar-
gets that control EMT.
Supporting Information
S1 Fig. Stability of internal control genes for qRT-PCR among RNA samples.Expression
level of three internal control genes in four RNA samples from A549 spheroids treated with 5
ng/mL TGF-β2 or the vehicle (0.1% BSA/4 mMHCL) and 10 μM SB431542 or DMSO were
evaluated by qRT-PCR. TBP was the most stable gene out of 3 among 4 RNA samples. Data are
mean ± SD of triplicate well.
(TIF)
S2 Fig. Spheroid area of pancreas cancer cell lines. Three pancreas cancer cell lines were cul-
tured on NCP and observedwith Celigo for image analysis. Pixels of these spheroids in a whole
well were measured as spheroid size with image J software, and then the mean and median
were calculated. Data are mean ± SD of triplicate well.
(TIF)
S3 Fig. Effect of four candidate drugs to spheroids in indicated doses.No EMT induction,
only drug treated spheroids hypoxia images (red color). A549 spheroids cultured on NCP for 3
days were treated with each drugs at indicated concentrations for 4 days. In 20 μM SU 9516
treatment, spheroid sizes were small.
(TIF)
S1 Movie. A549 Spheroids Morphology on NanoCulture Plate after treated with 0.1%
BSA / 4 mMHCL from day 3 to day 7 without TGF-β2 as a control. After cell seeding,
time-lapse images were taken every 2 hours for 4 days with BioStation CT (objective lens is
10×).
(ZIP)
S2 Movie. A549 SpheroidsMorphology change on NanoCulture Plate after treated with the
TGF-β2, 0.1% BSA/4 mMHCL from day 3 to day 7. Then time-lapse images were taken
every 2 hours for 4 days with BioStation CT objective lens is 10×).
(ZIP)
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